Dislipidemiler

Carl A. Burtis, David A. Bruns Tietz Fundamentals of Clinical Chemistry and Molecolar Diagnostics, Seventh Edition 401-407. Elsevier, 2014.

Mach, François & Baigent, Colin & Catapano, Alberico & Koskinas, Konstantinos & Casula, Manuela & Badimon, Lina & Chapman, Mr & De Backer, Guy & delgado, Victoria & Ference, Brian & Graham, Ian & Halliday, Alison & Landmesser, Ulf & Mihaylova, Borislava & Pedersen, Terje & Riccardi, Gabriele & Richter, Dimitrios & Sabatine, Marc & Taskinen, Marja-Riitta & Patel, Riyaz. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal. 41. 10.1093/eurheartj/ehz455.

Dislipidemi tanı ve tedavi kılavuzu, Türkiye Endokrinoloji ve Metabolizma Derneği, 2021.

Fredrickson, D. S., & Lees, R. S. (1965). A System for Phenotyping Hyperlipoproteınemıa. Circulation, 31,321327.https://doi.org/10.1161/01.cir.31.3.321

Başkal N. Lipid metabolizması bozuklukları. Erdoğan G. Koloğlu Endokrinoloji, Temel ve Klinik. 2. Baskı. Ankara: MN Medikal & Nobel, 2005: 755-73.

Burnett, J. R., Hooper, A. J., & Hegele, R. A. (1999). Familial Lipoprotein Lipase Deficiency. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.

Baggio, G., Manzato, E., Gabelli, C., Fellin, R., Martini, S., Enzi, G. B., Verlato, F., Baiocchi, M. R., Sprecher, D. L., & Kashyap, M. L. (1986). Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. The Journal of clinical investigation, 77(2), 520–527. https://doi.org/10.1172/JCI112332

Adult Treatment Panel (ATP) IV Eşliğinde Güncel Hiperlipidemi Tedavisi, Eur J Health Sci 2016;2(1):15-19

Brunner, F. J., Waldeyer, C., Ojeda, F., Salomaa, V., Kee, F., Sans, S., Thorand, B., Giampaoli, S., Brambilla, P., Tunstall-Pedoe, H., Moitry, M., Iacoviello, L., Veronesi, G., Grassi, G., Mathiesen, E. B., Söderberg, S., Linneberg, A., Brenner, H., Amouyel, P., Ferrières, J., … Multinational Cardiovascular Risk Consortium (2019). Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet (London, England), 394(10215), 2173–2183. https://doi.org/10.1016/S0140-6736(19)32519-X

Langlois, M., Nordestgaard, B., Langsted, A., Chapman, M., Aakre, K., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., Collinson, P., Descamps, O., Duff, C., von Eckardstein, A., Hammerer-Lercher, A., Kamstrup, P., Kolovou, G., Kronenberg, F., Mora, S., Pulkki, K., Remaley, A., Rifai, N., Ros, E., Stankovic, S., Stavljenic-Rukavina, A., Sypniewska, G., Watts, G., Wiklund, O., Laitinen, P. & for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative (2020). Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine (CCLM), 58(4), 496-517. https://doi.org/10.1515/cclm-2019-1253

Contois, J. H., & Delatour, V. (2018). Apolipoprotein B measurement: Need for standardization. Journal of clinical lipidology, 12(2), 264–265. https://doi.org/10.1016/j.jacl.2018.02.017